ARKG Holdings of Organovo (ONVO) - Updated Daily
Synthetic Biology3D Printing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 0% | $18.47m |
| 🏋🏿♂️Weight Rank In ARKG | 🌏Country |
| 45 | 🇺🇸United States |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 211 | $58.10 |
| 🎫ARK Ownership Percent | |
| 0% | |
| Description | |
|---|---|
| Organovo is an early-stage biotechnology company that is developing and utilizing highly customized 3D human tissues as dynamic models of healthy and diseased human biology for drug development. The company's proprietary technology is being used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Organovo's advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs for selected therapeutic areas. | |
| Website | |
| www.organovo.com |
Research Notes and Commentary for ONVO
No Research Notes Found for ONVO